Gene · 53345
Papers1,658
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
261 to 280 of 1,658
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| MicroRNAs Signature Panel Identifies Heavy Drinkers with Alcohol-Associated Cirrhosis from Heavy Drinkers without Liver Injury. | Biology (Basel) | 2023 | 37887024 | PubTator, text mining | PubMed |
| Practice guidance documents for the diagnosis and management of non-alcoholic fatty liver disease-recent updates and open questions. | Hepatobiliary Surg Nutr | 2023 | 37886211 | PubTator, text mining | PubMed |
| Multi-system diseases and death trajectory of metabolic dysfunction-associated fatty liver disease: findings from the UK Biobank. | BMC Med | 2023 | 37864216 | PubTator, text mining | PubMed |
| Macrophage specific restoration of the Nrf2 gene in whole-body knockout mice ameliorates steatohepatitis induced by lipopolysaccharide from Porphyromonas gingivalis through enhanced hepatic clearance. | PLoS One | 2023 | 37862331 | PubTator, text mining | PubMed |
| Histone Modifications in NAFLD: Mechanisms and Potential Therapy. | Int J Mol Sci | 2023 | 37834101 | PubTator, text mining | PubMed |
| Advancements in Diagnostic and Therapeutic Interventions of Non-alcoholic Fatty Liver Disease: A Literature Review. | Cureus | 2023 | 37814734 | PubTator, text mining | PubMed |
| Familial clustering of nonalcoholic fatty liver disease in first-degree relatives of adults with lean nonalcoholic fatty liver disease. | Liver Int | 2023 | 37804066 | PubTator, text mining | PubMed |
| Found in translation-Fibrosis in metabolic dysfunction-associated steatohepatitis (MASH). | Sci Transl Med | 2023 | 37792957 | PubTator, text mining | PubMed |
| The mitochondrial amidoxime reducing component-from prodrug-activation mechanism to drug-metabolizing enzyme and onward to drug target. | J Biol Chem | 2023 | 37778733 | PubTator, text mining | PubMed |
| Dietary Patterns, Foods, and Nutrients to Ameliorate Non-Alcoholic Fatty Liver Disease: A Scoping Review. | Nutrients | 2023 | 37764771 | PubTator, text mining | PubMed |
| New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut-Liver-Heart Crosstalk. | Nutrients | 2023 | 37764755 | PubTator, text mining | PubMed |
| Coagulation Dysfunctions in Non-Alcoholic Fatty Liver Disease-Oxidative Stress and Inflammation Relevance. | Medicina (Kaunas) | 2023 | 37763733 | PubTator, text mining | PubMed |
| Non-Alcoholic Fatty Liver Disease and Echocardiographic Parameters of Left Ventricular Diastolic Function: A Systematic Review and Meta-Analysis. | Int J Mol Sci | 2023 | 37762592 | PubTator, text mining | PubMed |
| Is the Development of Ascites in Alcoholic Liver Patients Influenced by Specific KIR/HLA Gene Profiles? | Biomedicines | 2023 | 37760846 | PubTator, text mining | PubMed |
| Advances in genetic variation in metabolism-related fatty liver disease. | Front Genet | 2023 | 37753315 | PubTator, text mining | PubMed |
| Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women. | Nat Med | 2023 | 37749332 | PubTator, text mining | PubMed |
| Alcohol-Associated Liver Disease: Evolving Concepts and Treatments. | Drugs | 2023 | 37747685 | PubTator, text mining | PubMed |
| Micropatterned primary hepatocyte co-culture (HEPATOPAC) for fatty liver disease modeling and drug screening. | Sci Rep | 2023 | 37739978 | PubTator, text mining | PubMed |
| Overview of hepatocellular carcinoma: from molecular aspects to future therapeutic options. | Cell Adh Migr | 2023 | 37726886 | PubTator, text mining | PubMed |
| Study on inflammation and fibrogenesis in MAFLD from 2000 to 2022: a bibliometric analysis. | Front Endocrinol (Lausanne) | 2023 | 37720529 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/53345/papers?page=14